echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Qilu broke out!

    Qilu broke out!

    • Last Update: 2021-06-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
      A few days ago, the State Food and Drug Administration's official website showed that Qilu Pharmaceutical's cefazolin sodium for injection has been approved as a supplementary application, and this product is the third domestically-evaluated company.
    According to data from Meinenet, in 2020, the sales of cefazolin sodium for terminal injection in public medical institutions in China will exceed 1.
    5 billion yuan.
    There are more than 60 manufacturers of cefazolin sodium for injection.
    At present, only Chengdu Better Pharmaceutical, Guangdong Jincheng Jinsu Pharmaceutical and Qilu Pharmaceutical have been approved for supplementary applications.
    It is worth mentioning that this product is the eighth injection product reviewed by Qilu Pharmaceutical in May.
    At present, Qilu Pharmaceutical has 76 products passed or deemed to have passed the consistency evaluation, of which 35 are the first in China.
     
     
     May 31, 2021 drug approval documents to be collected information released
     
      Cefazolin sodium for injection belongs to the first-generation cephalosporin antibiotics.
    It is clinically used to treat respiratory tract infections, urinary tract infections, bone and joint infections, sepsis and reproductive system infections caused by sensitive bacteria.
     
      Sales of Cefazolin Sodium for Terminal Injection in Public Medical Institutions in China in Recent Years
      Source: The terminal competition pattern of China's public medical institutions
     
      According to data from Meinenet, in recent years , the sales of cefazolin sodium for terminal injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have maintained a growth rate of more than 10% in 2020.
    More than 1.
    5 billion yuan.
    Among them, China Resources Jiuxin Pharmaceutical, Shenzhen Lijian Pharmaceutical, and Chengdu Better Pharmaceutical have the top three market shares.
     
      
    Source: Meinenet MED2.
    0 Chinese Drug Evaluation Database
     
      Sodium for Injection Cefazolin manufacturers have more than 60 at present, only Chengdu Brilliant Pharmaceutical, Guangdong Jincheng Kim Su pharmaceutical and Qilu Pharmaceutical three companies to supplement the application is approved through the comment.
    In addition, the supplementary applications for consistency evaluation of 5 companies including Sinopharm Group Zhongnuo Pharmaceutical and Harbin Pharmaceutical Group Pharmaceutical General Factory are under review and approval.
    Shenzhen China Resources Jiuxin Pharmaceutical | Zhejiang China Resources Sanjiu Zhongyi Pharmaceutical has imitated 3 categories The submission of the listing application is under review and approval, and it will be deemed as over-evaluated after it is approved.
     
      Source: official website of the State Food and Drug Administration, Mi Nei.
    com database
      A few days ago, the State Food and Drug Administration's official website showed that Qilu Pharmaceutical's cefazolin sodium for injection has been approved as a supplementary application, and this product is the third domestically-evaluated company.
    According to data from Meinenet, in 2020, the sales of cefazolin sodium for terminal injection in public medical institutions in China will exceed 1.
    5 billion yuan.
    There are more than 60 manufacturers of cefazolin sodium for injection.
    At present, only Chengdu Better Pharmaceutical, Guangdong Jincheng Jinsu Pharmaceutical and Qilu Pharmaceutical have been approved for supplementary applications.
    It is worth mentioning that this product is the eighth injection product reviewed by Qilu Pharmaceutical in May.
    At present, Qilu Pharmaceutical has 76 products passed or deemed to have passed the consistency evaluation, of which 35 are the first in China.
     
     
     May 31, 2021 drug approval documents to be collected information released
     
      Cefazolin sodium for injection belongs to the first-generation cephalosporin antibiotics.
    It is clinically used to treat respiratory tract infections, urinary tract infections, bone and joint infections, sepsis and reproductive system infections caused by sensitive bacteria.
     
      Sales of Cefazolin Sodium for Terminal Injection in Public Medical Institutions in China in Recent Years
      Source: The terminal competition pattern of China's public medical institutions
     
      According to data from Meinenet, in recent years , the sales of cefazolin sodium for terminal injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have maintained a growth rate of more than 10% in 2020.
    More than 1.
    5 billion yuan.
    Among them, China Resources Jiuxin Pharmaceutical, Shenzhen Lijian Pharmaceutical, and Chengdu Better Pharmaceutical have the top three market shares.
     
      
    Source: Meinenet MED2.
    0 Chinese Drug Evaluation Database
     
      Sodium for Injection Cefazolin manufacturers have more than 60 at present, only Chengdu Brilliant Pharmaceutical, Guangdong Jincheng Kim Su pharmaceutical and Qilu Pharmaceutical three companies to supplement the application is approved through the comment.
    In addition, the supplementary applications for consistency evaluation of 5 companies including Sinopharm Group Zhongnuo Pharmaceutical and Harbin Pharmaceutical Group Pharmaceutical General Factory are under review and approval.
    Shenzhen China Resources Jiuxin Pharmaceutical | Zhejiang China Resources Sanjiu Zhongyi Pharmaceutical has imitated 3 categories The submission of the listing application is under review and approval, and it will be deemed as over-evaluated after it is approved.
     
      Source: official website of the State Food and Drug Administration, Mi Nei.
    com database
      A few days ago, the State Food and Drug Administration's official website showed that Qilu Pharmaceutical's cefazolin sodium for injection has been approved as a supplementary application, and this product is the third domestically-evaluated company.
    According to data from Meinenet, in 2020, the sales of cefazolin sodium for terminal injection in public medical institutions in China will exceed 1.
    5 billion yuan.
    There are more than 60 manufacturers of cefazolin sodium for injection.
    At present, only Chengdu Better Pharmaceutical, Guangdong Jincheng Jinsu Pharmaceutical and Qilu Pharmaceutical have been approved for supplementary applications.
    It is worth mentioning that this product is the eighth injection product reviewed by Qilu Pharmaceutical in May.
    At present, Qilu Pharmaceutical has 76 products passed or deemed to have passed the consistency evaluation, of which 35 are the first in China.
     
     
     May 31, 2021 drug approval documents to be collected information released
     
      Cefazolin sodium for injection belongs to the first-generation cephalosporin antibiotics.
    It is clinically used to treat respiratory tract infections, urinary tract infections, bone and joint infections, sepsis and reproductive system infections caused by sensitive bacteria.
     
      Sales of Cefazolin Sodium for Terminal Injection in Public Medical Institutions in China in Recent Years
      Source: The terminal competition pattern of China's public medical institutions
     
      According to data from Meinenet, in recent years , the sales of cefazolin sodium for terminal injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have maintained a growth rate of more than 10% in 2020.
    More than 1.
    5 billion yuan.
    Among them, China Resources Jiuxin Pharmaceutical, Shenzhen Lijian Pharmaceutical, and Chengdu Better Pharmaceutical have the top three market shares.
    Hospital hospital hospital
     
      
    Source: Meinenet MED2.
    0 Chinese Drug Evaluation Database
     
      Sodium for Injection Cefazolin manufacturers have more than 60 at present, only Chengdu Brilliant Pharmaceutical, Guangdong Jincheng Kim Su pharmaceutical and Qilu Pharmaceutical three companies to supplement the application is approved through the comment.
    In addition, the supplementary applications for consistency evaluation of 5 companies including Sinopharm Group Zhongnuo Pharmaceutical and Harbin Pharmaceutical Group Pharmaceutical General Factory are under review and approval.
    Shenzhen China Resources Jiuxin Pharmaceutical | Zhejiang China Resources Sanjiu Zhongyi Pharmaceutical has imitated 3 categories The submission of the listing application is under review and approval, and it will be deemed as over-evaluated after it is approved.
    Enterprise business enterprise
     
      Source: official website of the State Food and Drug Administration, Mi Nei.
    com database
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.